Immunotherapy drug doubles cancer-free survival in head and neck cancer patients
BBC - 31-May-2025Pembrolizumab doubled cancer-free survival from 2.5 to 5 years and cut spread risk by 10%
Join the club for FREE to access the whole archive and other member benefits.
Pembrolizumab doubled cancer-free survival from 2.5 to 5 years and cut spread risk by 10%
No resources found!
No blog posts found!